Navigation Links
New therapeutic options for newly diagnosed multiple myeloma patients
Date:12/10/2007

ATLANTA -- Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy. The findings were reported by Craig B. Reeder, M.D., at the American Society of Hematologys annual meeting.

For newly diagnosed multiple myeloma patients, this new treatment provides a more frequent, rapid and deeper response when compared to earlier treatment options, says Dr. Reeder, a Mayo Clinic Cancer Center hematologist/oncologist and lead investigator of the study. This is the first time we have studied this treatment in newly diagnosed patients with this condition. Compared with past therapies, this new treatment proved to be very successful.

The team studied 30 patients receiving Cybor-D in the trial. As a relevant contemporaneous control for speed and depth of response, researchers compared 34 patients treated on a recent Mayo Clinic trial of L-Dex. The findings showed that Cybor-D produced a rapid initial decline and percentage reduction in M protein (abnormal protein present in blood of myeloma patients) and a significantly higher rate of good or complete responses than L-Dex. Prophylactic use of acyclovir, a quinolone and antifungal prophylaxis was highly recommended for all patients on the study.


'/>"/>

Contact: Jenny Ho
newsbureau@mayo.edu
480-301-4368
Mayo Clinic
Source:Eurekalert

Page: 1

Related medicine news :

1. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
2. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
10. Prime Therapeutics Announces URAC Accreditation
11. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein ... to families and business professionals throughout central Colorado, is joining local nonprofit Aurora ... The Aurora Warms The Night organization is committed to breaking the cycle of ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , the ... in real-time, today announced a strategic partnership with TechLab Security, a ... Seceon partners, TechLab Security has become a strategic partner and a value added ...
(Date:1/17/2017)... New York, NY (PRWEB) , ... January 17, ... ... of Inc. Magazine’s fastest-growing private companies and ranked among the top US security ... first Board of Directors. This announcement brings a year-long independent board nomination ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... the Montclair State University’s Athletic Training Education program forged a relationship built upon ... Education Program, which is consists of both student members and certified members ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... GRAND RAPIDS, Mich. , Jan. 17, 2017 ... of Richard M. Erwin as Vice ... Catalyst Pharmaceuticals, where he was Executive Director, Clinical Project Management. ... with over 25 years of experience in global ... a string of successful growth-stage clinical operation build-outs ...
(Date:1/17/2017)...  Bayer today announced the appointment of Dr. Carsten ... Americas, comprising the United States , ... . In this role, Dr. Brunn will report to ... of Bayer AG and President of the Pharmaceutical division. ... the pharmaceutical industry and I,m delighted to have him lead ...
(Date:1/16/2017)... 2017 Research and Markets has announced the ... report to their offering. ... Global multiple myeloma drugs market to grow at a ... report covers the present scenario and the growth prospects of the ... size, the report considers the revenue generated from the sales of ...
Breaking Medicine Technology: